The Global Anti-Obesity Drug Market is Anticipated to Witness Robust Growth Due to Rising Prevalence of Obesity

The Global Anti-Obesity Drug Market is Anticipated to Witness Robust Growth Due to Rising Prevalence of Obesity

These drugs help reduce appetite, increase metabolism, or decrease the absorption of fat from the diet. The global anti-obesity drug market is witnessing an increase in demand for anti-obesity drugs due to the rising prevalence of obesity caused by sedentary lifestyle and unhealthy eating habits.

The Global anti-obesity drug market is estimated to be valued at US$ 2928.39 Million in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2031.

Key Takeaways

Key players: Key players operating in the anti-obesity drug market are ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others.

Key opportunities: The Anti-Obesity Drugs Market Size holds lucrative opportunities owing to the rising awareness regarding obesity and weight management. Additionally, technological advancements in novel drug delivery methods are further expected to boost demand.

Global expansion: To tap the growing demand for anti-obesity drugs worldwide, key players are expanding their geographical reach through acquisitions, collaborations, and partnerships. Strategic alliances with local players are helping companies strengthen their global foothold.

Market drivers: The increasing prevalence of obesity, coupled with rising health consciousness among consumers, are the key factors driving the growth of the anti-obesity drug market. Furthermore, co-morbidities associated with obesity, such as diabetes and cardiovascular diseases, are also contributing to market growth.

Market restrain: However, the growth of this market may get hampered due to the reluctance of insurance companies to cover off-label uses of anti-obesity drugs and undesirable side effects associated with few anti-obesity drugs such as heart issues, psychiatric issues and suicidal thoughts. Stringent regulations pertaining to the approval of anti-obesity drugs also pose challenges to market players.

Segment Analysis

The anti-obesity drug market can be segmented by drug class into peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. The peripherally acting anti-obesity drugs segment is currently dominating due to high efficacy and minimal side effects of drugs such as orlistat. Orlistat works by inhibiting pancreatic lipases thereby reducing dietary fat absorption in the gastrointestinal tract by around 30%. This leads to reduced calorie intake and modest weight loss.

Global Analysis

The North American region currently dominates the global anti-obesity drug market due to high obesity rates, growing awareness about obesity management, and easy availability of anti-obesity drugs in the region. The region is expected to retain its dominance during the forecast period as well owing to rising per capita healthcare expenditure and continuous new drug approvals. The Asia Pacific region is expected to witness the fastest growth during the forecast period. This can be attributed to growing obesity problem coupled with rising disposable incomes in emerging countries like China and India. Increasing awareness regarding obesity risks and its management is also expected to support market growth in the Asia Pacific region.
Get more insights on This Topic- Anti-Obesity Drugs Market